Paul Connelly
LightNews LightNews
pconnelly.bsky.social
Paul Connelly
@pconnelly.bsky.social
83 followers 150 following 14 posts
Consultant Endocrinologist - Glasgow

Interested in sex steroids, pituitary disease and mineral metabolism.
Posts Replies Media Videos
pconnelly.bsky.social
Hypoparanoid - anxiety relating to calcium results
March 3, 2025 at 9:37 PM
pconnelly.bsky.social
Attended the brilliant Reproductive Endocrinology meeting in London. Superb speakers and topics. Excited to put this new knowledge into practice! #endosky #medsky
December 3, 2024 at 5:56 PM
pconnelly.bsky.social
It's my first Christmas as a consultant.

What do I get my amazing secretary?

#medsky
November 22, 2024 at 8:45 AM
pconnelly.bsky.social
You do wonder about how the pancreas copes with hypercalcaemia in PHP
November 18, 2024 at 9:01 PM
pconnelly.bsky.social
Higher risk of incident diabetes among patients with primary hyperparathyroidism
Objectives There is relatively scarce data regarding the association between primary hyperparathyroidism (PHPT) and incident diabetes in large population-based longitudinal studies. We aimed to eval.....
onlinelibrary.wiley.com
November 18, 2024 at 8:55 PM
Reposted by Paul Connelly
erictopol.bsky.social
Another GLP-1 drug success. Tirzepatide in heart failure with preserved ejection fraction (HFpEF) with longer term follow-up than 2 previous trials with semaglutide
nejm.org/doi/full/10....
in people with BMI >30; no data yet for HFpEF in people without obesity
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity | NEJM
Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor...
nejm.org
November 16, 2024 at 3:12 PM
pconnelly.bsky.social
Sequential zoledronic acid following densoumab did not prevent loss of lumbar spine BMD @jamacurrent.bsky.social
Zoledronate Sequential Therapy to Prevent Bone Loss After Stopping Denosumab
This randomized clinical trial examines the use of sequential therapy with zoledronate to prevent loss of bone mineral density after denosumab discontinuation in the first year.
jamanetwork.com
November 16, 2024 at 1:44 PM